Cargando…
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of coronary artery disease. However, despite increasing use of statins, a significant number of coronary events still occur...
Autores principales: | Tenenbaum, Alexander, Fisman, Enrique Z, Motro, Michael, Adler, Yehuda |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1592077/ https://www.ncbi.nlm.nih.gov/pubmed/17002798 http://dx.doi.org/10.1186/1475-2840-5-20 |
Ejemplares similares
-
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
por: Tenenbaum, Alexander, et al.
Publicado: (2012) -
Statins research unfinished saga: desirability versus feasibility
por: Fisman, Enrique Z, et al.
Publicado: (2005) -
Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
por: Tenenbaum, Alexander, et al.
Publicado: (2003) -
Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
por: Tenenbaum, Alexander, et al.
Publicado: (2004) -
Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus
por: Tenenbaum, Alexander, et al.
Publicado: (2003)